Our Network of Consultants

• Director-level Competitive Intelligence (CI) leader with 14+ years of pharma/ biotech industry experience in oncology and immuno-oncology (IO). Including over 6 and a half years specialising in competitive intelligence,
clinical data insights, evidence synthesis, and strategic analysis to inform evidence-based decision-making, and over 7 years in preclinical drug discovery.
• Deep domain expertise in oncology therapeutics (for solid tumours and haematological malignancies), covering a global pipeline, with acute understanding of several treatment modalities including antibody-drug conjugates, monoclonal antibodies, bispecifics, chemotherapy, hormonal therapy, cell therapy and small molecules.
• 7+ years of leadership experience on various dimensions, including team leadership, line managing direct reports, leading an IO CI function, expanding the scope and influence of an insights function, drug discovery
project leadership, project management, stakeholder and external vendor management, hiring and mentoring junior colleagues, fostering capability building within a team, delegating work effectively, improving integrated
insights processes (Six Sigma Yellow Belt), and driving adoption of new systems to improve evidence-based decision-making and maximise the strategic value of competitor information.
• Proven track record of collaborating with senior leadership (Senior Director, VP and C-suite) and other key partners from several functions (medical, clinical development, Business Development, publications, and Investor
Relations), to deliver actionable insights, and support clinical trial planning, portfolio asset prioritisation, lifecycle management, and corporate strategy activities.
• Led or supported numerous initiatives aiming to develop commercial and clinical strategy, including epidemiology analyses for patient population sizing, updating standard of care (SOC) efficacy hurdle in several
target product profiles (TPPs), providing evidence for trial diversity planning, or indication prioritisation.
• Extensive experience monitoring competitor pipeline assets (from preclinical research through commercialisation), integrating and analysing scientific literature, clinical, regulatory, commercial, and
investment banking reports data, into recommendations and delivering forward-looking competitive insights that shape clinical strategy and inform portfolio investment decisions.
• Specialised in translating complex quantitative and qualitative scientific, clinical trial, or industry data into high quality executive-level deliverables and communicating this information effectively to technical and
non-technical stakeholders, to ensure a full understanding of the constantly evolving oncology landscape.
• Proficiency with best-in-class external data sources (Norstella suite, Clarivate tools, GlobalData, Clinicaltrials.gov, Article Galaxy, Kantar, Medline, Embase, PubMed, Scopus, …), and data visualisation tools (Power BI, Tableau), and statistical tools (GraphPad Prism, Minitab, Excel) used in leading Pharma companies like AstraZeneca.
• Combines strong scientific background in IO research and development, analytical rigour, and critical thinking with a proven ability to influence cross-functional decision-making without authority, and providing transparency and respectful challenge to key decision makers in a matrixed global environment.
• Strong business acumen, and deep understanding of strategic corporate priorities, having supported fundraising activities, led scientific and strategic due diligence on 2 merger and acquisition transactions (including one
leading to an IPO on Nasdaq), supported differentiation messaging for investor relations communication, and helped VP and C-suite senior leaders make data-driven decisions with agility and impact.

I work with life sciences and biotech companies as a fractional CFO and finance director. With 16 years of experience across EMEA operations including financial director and supply chain finance roles within global life sciences businesses, I bring enterprise level finance capability to growing companies without the cost of a full time hire.
I help founders and leadership teams with investor ready financial reporting, budgeting and forecasting, audit readiness, cash flow management, board reporting, EMEA multi entity operations and UK subsidiary setup for overseas businesses.
I am dual qualified ACA and FCCA with an Executive MBA from London Business School. I work with companies typically between £5m and £50m revenue at key growth and funding stages.

My area of study is the intersection of clinical neuroscience, translational pharmacology, and computational biomarker discovery. I am a PhD candidate investigating how glymphatic and meningeal–lymphatic pathways relate to neuroinflammation in humans. I focus on immune-cell phenotyping and cell-free markers that may index inflammatory activity and neurodegenerative trajectories. Alongside sampling development, I contribute to assay and workflow optimisation for mass-spectrometry-ready proteomics, with an emphasis on automation, quality control, and reproducibility.

My pharmacology and drug-safety foundation was built through an MRes in Biological Science and Translational Medicine. I examined dose- and time-dependent paracetamol-induced kidney injury in renal cell models, differentiating apoptotic and necrotic mechanisms and linking experimental readouts to clinically relevant nephrotoxicity questions. I completed a systematic review on cilastatin as a renoprotective strategy and critically evaluated in vitro acute kidney injury models for translational validity. I also gained ward-level exposure as a Clinical Research Associate in nephrology, aligning laboratory findings with real-world clinical pathways and multidisciplinary decision-making.

From an industry and communications perspective, I have experience in medical affairs-adjacent work, including market analysis to support launch planning in an ophthalmic pharmaceutical company and the development of compliant training materials with medical teams. I have delivered conference and hospital presentations, tailoring complex findings to both clinical and public audiences, and I have completed structured projects on European compliance frameworks, which underpins my approach to regulatorily aware medical writing.

Computationally, I build end-to-end machine-learning workflows in Python and R for noisy, high-dimensional datasets, particularly proteomics and multimodal clinical data. My toolkit spans supervised learning, unsupervised clustering, and dimensionality reduction.

Overall, my expertise is translating complex biomedical and quantitative evidence into actionable deliverables, supported by an MBA in Clinical Leadership and a strong biochemistry foundation, including earlier research on TEX12 expression in somatic and cancer models.

Physician | Clinical Scientist | Vaccine & Biologics Development

Physician and clinical scientist with over 15 years of international experience across the full spectrum of vaccine and biologics development, from early-phase innovation to late-phase clinical implementation. Currently serving as Clinical Science Lead at GSK Vaccines (Italy), providing strategic and scientific leadership for late-phase clinical trials in meningococcal disease and other vaccine-preventable infections.

My professional background includes early clinical development programs addressing antimicrobial resistance and neglected tropical diseases, with hands-on experience in monoclonal antibodies and innovative delivery strategies. I have contributed to more than 40 clinical trials across Latin America, Europe, and complex or conflict-affected settings, including investigator-initiated studies, the establishment of clinical research centers, and collaborations with global health organizations such as WHO and DNDi.

I hold formal training in epidemiology and global health, with solid regulatory experience interacting with FDA, EMA, and WHO frameworks. My work is guided by scientific rigor, operational excellence, and a strong commitment to public health impact.

I am particularly interested in the intersection of clinical development, data science, and digital innovation to improve clinical decision-making in immunology and translational medicine. I value cross-functional collaboration, ethical leadership, and mission-driven science, and I am always open to scientific exchange and global partnerships that advance equitable access to transformative health solutions.

A PhD consultant in the biotechnology and life sciences industry with over 17 years of experience working internationally. Specializing in customer insights, market-driven product development and strategic marketing, with expertise in genomic medicine, gene therapy, cell therapy, nanomedicine, NGS, molecular diagnostics, oncology, and more. Held leadership positions in biotech and life sciences companies in Canada, US and UK, including Abcam, STEMCELL Technologies, Thermo Fisher Scientific, Cytiva/Danaher.

I have a a D.Phil. in Biochemistry from the University of Oxford with first author publication in Nature Immunology; an MSc from University of Toronto and a BSc (Honours) from University of British Columbia.

Consulting Services include:
Voice of Customer/Customer Insights
Market Driven Product Requirements
Value Propositions and Product Positioning
Product-Market fit
Competitor Landscape Assessments
Pricing Strategies
Go to Market Strategies